Infectious adverse events in patients with atopic dermatitis treated with baricitinib
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infectious adverse events in patients with atopic dermatitis treated with baricitinib
Authors
Keywords
-
Journal
Immunotherapy
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2023-10-18
DOI
10.2217/imt-2023-0078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expert Consensus on the Systemic Treatment of Atopic Dermatitis in Special Populations
- (2023) D. N. Adam et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- (2023) Peter C. Taylor et al. ADVANCES IN THERAPY
- Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan
- (2023) Teppei Hagino et al. JOURNAL OF DERMATOLOGY
- Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
- (2022) Danielle Rogner et al. ACTA DERMATO-VENEREOLOGICA
- Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis
- (2022) Cristina Garufi et al. Expert Review of Clinical Immunology
- Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
- (2022) Yoshiya Tanaka et al. Nature Reviews Rheumatology
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
- (2022) Sheridan M. Hoy AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Herpesvirus, serious and opportunistic infections associated with atopic dermatitis
- (2022) Natalija Novak et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate‐to‐Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo‐Controlled , Phase III Clinical Trial ( BREEZE‐AD4 )
- (2022) Thomas Bieber et al. BRITISH JOURNAL OF DERMATOLOGY
- Real‐world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single‐center retrospective study
- (2022) Akihiko Uchiyama et al. JOURNAL OF DERMATOLOGY
- An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate‐to‐severe atopic dermatitis
- (2022) T. Werfel et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Application of Baricitinib in Dermatology
- (2022) Jingya Zhang et al. Journal of Inflammation Research
- A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
- (2022) Thomas Bieber et al. ADVANCES IN THERAPY
- European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
- (2022) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
- (2022) Norito Katoh et al. Dermatology and Therapy
- Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
- (2022) Celeste M. Boesjes et al. ACTA DERMATO-VENEREOLOGICA
- Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
- (2022) Thomas Bieber et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Long‐term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate‐to‐severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE‐AD7
- (2022) Jonathan I. Silverberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)
- (2021) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
- (2021) Brett King et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Baricitinib: From Rheumatoid Arthritis to COVID‐19 5
- (2021) Sara Assadiasl et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomised trial
- (2021) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Atopic Dermatitis
- (2021) Sonja Ständer NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors in the Treatment of Atopic Dermatitis
- (2021) R. Chovatiya et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The infection risks of JAK inhibition
- (2021) Maryam A. Adas et al. Expert Review of Clinical Immunology
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- New treatments in atopic dermatitis
- (2020) Neha Puar et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
- (2020) T. Bieber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
- (2020) K. Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Skin Diseases associated with Atopic Dermatitis
- (2018) Justine Fenner et al. CLINICS IN DERMATOLOGY
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders
- (2018) Amy Paller et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search